• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Active Biotech

5.83 SEK

-4.35 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.35 %
-17.30 %
+37.18 %
+26.74 %
+29.56 %
-61.97 %
-77.11 %
-87.11 %
-98.59 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Read more
Market cap
153.68M SEK
Turnover
255.71K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

11/2
2027

Annual report '26

Regulatory press release5/28/2026, 6:30 AM

Active Biotech offentliggör tidplan för sammanläggning av aktier

Active Biotech
Regulatory press release5/28/2026, 6:30 AM

Active Biotech announces timetable for reverse share split

Active Biotech
Regulatory press release5/20/2026, 4:30 PM

Årsstämma i Active Biotech AB

Active Biotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/20/2026, 4:30 PM

Annual General Meeting of Active Biotech AB

Active Biotech
Third party research5/18/2026, 7:19 AM

Active Biotech: Jakt på partnerskap - Analysguiden

Active Biotechs ögonprojekt redovisade nyligen data från en biodistributionsstudie i ett litet antal deltagare. Forskarnas kommentarer tillåter oss att behålla positiva prognoser och det optimistiska antagandet att projektet kan säljas senare i år. Samtidigt...

Active Biotech
Press release5/18/2026, 7:00 AM

Analysguiden: ANALYS Active Biotech: Jakt på partnerskap

Active Biotech
Press release5/13/2026, 9:30 AM

Europeiskt regulatoriskt godkännande har erhållits för att återuppta rekryteringen i HOVON 172 MF-studien med tasquinimod i myelofibros som genomförs i samarbete mellan Active Biotech, Oncode och HOVON

Active Biotech
Press release5/13/2026, 9:30 AM

European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON

Active Biotech
Press release5/8/2026, 8:14 AM

Redeye: Active Biotech (Q1 Review): Intensified Focus on Business Development

Active Biotech
Regulatory press release5/7/2026, 6:30 AM

Active Biotech Delårsrapport Q1 2026

Active Biotech
Regulatory press release5/7/2026, 6:30 AM

Active Biotech Interim Report Q1 2026

Active Biotech
Press release4/20/2026, 9:30 AM

Active Biotech publicerar resultat från LION-studien om okulär absorption och distribution av laquinimod i ögat

Active Biotech
Press release4/20/2026, 9:30 AM

Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye

Active Biotech
Regulatory press release4/17/2026, 12:30 PM

KALLELSE TILL ÅRSSTÄMMA

Active Biotech
Regulatory press release4/17/2026, 12:30 PM

NOTICE OF ANNUAL GENERAL MEETING

Active Biotech
Regulatory press release4/1/2026, 7:30 AM

Årsredovisning 2025 Active Biotech AB (publ)

Active Biotech
Regulatory press release4/1/2026, 7:30 AM

Annual Report 2025 Active Biotech AB (publ)

Active Biotech
Third party research2/20/2026, 10:25 AM

Active Biotech: Studie startar på nytt - Analysguiden

Den amerikanska delen av Active Biotechs myelofibros-projekt har fått tillstånd att starta rekrytering av nya patienter efter ett tio månader långt uppehåll. Vi räknar inom kort med omstart för även den europeiska studien. Under året ser vi också en ...

Active Biotech
Press release2/20/2026, 9:40 AM

Analysguiden: ANALYS Active Biotech: Studie startar på nytt

Active Biotech
Press release2/13/2026, 12:08 PM

Redeye: Active Biotech (Q4 Review): Tasqinimod Recruiting Again

Active Biotech